Drug
Lanreotide clinical trials
Also written Somatuline and Somatuline Depot.
- studies test it
- 40
- open now
- 2
- in phase 3
- 17
- first study started
- 2000
Keep track of what changes. Save the lanreotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
40 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 5 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 22
- Phase 3
- 17
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 20
Ipsen (19) · Radboud University Medical Center (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Antonio Fojo (1) · Assistance Publique - Hôpitaux de Paris (1) · Duke University (1) · Ionis Pharmaceuticals, Inc. (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Cabozantinib (2) · Pembrolizumab (1) · Cimdelirsen (1) · Pegvisomant (1) · Temozolomide (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses lanreotide is read from its arms, and is right about nine times in ten.
Testing it · 40
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingPhase 1/2National Health Research Institutes, TaiwanNCT05048901Written as Lanreotide
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaRecruitingPhase 3SWOG Cancer Research NetworkNCT06807437Written as Lanreotide
- Lanreotide In Polycystic Kidney Disease StudyCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT02127437Written as Lanreotide
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)Active, not recruitingPhase 2Antonio FojoNCT03946527Written as Lanreotide
- Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursCompletedPhase 3IpsenNCT00353496Written as lanreotide (Autogel formulation)
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedPhase 2SCRI Development Innovations, LLCNCT02859064Written as Lanreotide
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedPhase 1/2Duke UniversityNCT03043664Written as Lanreotide
- Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT03967249Written as Somatostatin Receptor Ligand (SRL)
- SOMATULINE Autogel 90 mg IN DUMPING SYNDROMECompletedPhase 2Universitaire Ziekenhuizen KU LeuvenNCT01923649Written as Lanreotide 90 mg slow release formulation
- A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)TerminatedPhase 2/3Federation Francophone de Cancerologie DigestiveNCT02288377Written as lanreotide
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeCompletedPhase 3IpsenNCT00774930Written as Lanreotide
- Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine TumourCompletedPhase 3IpsenNCT00842348Written as lanreotide (Autogel formulation)
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedPhase 3IpsenNCT00383708Written as lanreotide (Autogel formulation)
- Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursTerminatedPhase 3IpsenNCT02683941Written as Lanreotide (Autogel formulation)
- A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.TerminatedPhase 4Saint John's Cancer InstituteNCT01861717Written as lanreotide
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownPhase 2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT04427787Written as Lanreotide
- The MetNET-2 TrialStatus unknownEarly Phase 1Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT02823691Written as Lanreotide and Metformin
- Lanreotide in the Treatment of Small Bowel Motility DisordersCompletedPhase 2Northwell HealthNCT03012594Written as Lanreotide
- Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedPhase 3IpsenNCT00447499Written as Somatuline Autogel (lanreotide acetate)
- Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal CarcinomatosisCompletedPhase 3IpsenNCT00216372Written as Lanreotide (microparticle formulation)
See all 40 studies that test lanreotide →
Given in every arm · 5 — lanreotide is usual care beside what is tested
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedPhase 1Debiopharm International SANCT05364944Written as Somatuline ATG
- Acromegaly Combination Treatment StudyTerminatedNot applicableCedars-Sinai Medical CenterNCT01538966Written as Lanreotide
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT04065165Written as Lanreotide
- Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary AdenomaStatus unknownPhase 3Samsung Medical CenterNCT03439709Written as Lanreotide 60Mg Solution for Injection
- A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid TumorsStatus unknownPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT01731925Written as Lanreotide
As the comparator · 2 — what is tested is compared with lanreotide
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Lanreotide
- Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyCompletedPhase 3IpsenNCT02493517Written as Lanreotide Acetate
Codes
What other systems call lanreotide · ClinicalTrials.gg INT003451
- MeSH (NLM) C060347lanreotideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0G3DE8943YLANREOTIDEConfirmed FDA, NLM
- RxNorm 68092One source FDA
- NCI Thesaurus C1523LanreotideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C060347 | lanreotide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0G3DE8943Y | LANREOTIDE | Confirmed FDA, NLM |
| RxNorm | 68092 | — | One source FDA |
| NCI Thesaurus | C1523 | Lanreotide | One source FDA |
Also registered as lanreotide acetate (UNII IEU56G3J9C · RxNorm 236167).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.